Factors associated with clearance of hepatitis B virus surface antigen in patients infected with human immunodeficiency virus.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
17 Jul 2020
17 Jul 2020
Historique:
entrez:
25
7
2020
pubmed:
25
7
2020
medline:
4
8
2020
Statut:
ppublish
Résumé
Owing to similar routes of transmission, hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection commonly occurs. Compared with patients infected with only HBV, coinfected patients develop persistent HBV infection followed by advanced liver diseases. However, the characteristics of HIV-infected patients who can achieve the clearance of HBV surface antigen (HBsAg) have not been clarified. In this study, we retrospectively examined patients coinfected with HBV and HIV and determined the host factors associated with HBsAg clearance.Among HIV-infected patients who visited our hospital between 1994 and 2017, we examined medical records of those who were seropositive for HBsAg at least once. Among them, patients who cleared HBsAg afterward were regarded as "cured," while those who remained HBsAg-seropositive until 2017 were "chronic."HBsAg seropositivity was found in 57 patients, and among them, 27 male patients were cured whereas 18 were chronic. The cured patients were significantly younger and had higher CD4 cell and platelet counts than the chronic patients. In addition, the cured patients had higher levels of transaminases after the detection of HBsAg. Multivariate analysis revealed age as an independent factor. Analyses of the patients infected with genotype A also showed that the cured patients had significantly higher CD4 cell counts.Considering that the CD4 cell and platelet counts were higher in the cured patients, immunological and liver functions were closely associated with HBsAg clearance. Higher levels of transaminases in the cured patients may also reflect the immunological function leading to HBsAg clearance.
Identifiants
pubmed: 32702915
doi: 10.1097/MD.0000000000021271
pii: 00005792-202007170-00110
pmc: PMC7373618
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21271Références
Clin Infect Dis. 2005 Oct 1;41(7):1045-8
pubmed: 16142673
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):437-43
pubmed: 26990826
N Engl J Med. 2012 May 10;366(19):1749-52
pubmed: 22571198
Hepatology. 2009 May;49(5 Suppl):S138-45
pubmed: 19399813
Medicine (Baltimore). 2018 May;97(1S Suppl 1):S16-S24
pubmed: 29794601
Lancet Infect Dis. 2005 Jun;5(6):374-82
pubmed: 15919623
Medicine (Baltimore). 2019 Aug;98(32):e16813
pubmed: 31393412
BMJ Open Gastroenterol. 2017 Oct 26;4(1):e000166
pubmed: 29119002
J Infect Chemother. 2019 Aug;25(8):646-648
pubmed: 31003957
Medicine (Baltimore). 2020 Feb;99(9):e19341
pubmed: 32118769
Medicine (Baltimore). 2018 May;97(1S Suppl 1):S3-S8
pubmed: 29912817
N Engl J Med. 2007 Apr 5;356(14):1445-54
pubmed: 17409326
PLoS One. 2012;7(8):e43143
pubmed: 22905219
Clin Infect Dis. 2013 Jun;56(12):1812-9
pubmed: 23487374
J Med Virol. 2005 May;76(1):33-9
pubmed: 15779048
Nat Genet. 2009 May;41(5):591-5
pubmed: 19349983
J Clin Microbiol. 2009 May;47(5):1476-83
pubmed: 19297602
Gastroenterology. 2003 Aug;125(2):444-51
pubmed: 12891547
J Med Virol. 1990 Jun;31(2):109-11
pubmed: 2143776
J Infect Dis. 2003 Aug 15;188(4):571-7
pubmed: 12898445
Sci Rep. 2019 Aug 16;9(1):11942
pubmed: 31420570
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:123-30
pubmed: 21199523
Antiviral Res. 2010 Jan;85(1):303-15
pubmed: 19887087
Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):237-9
pubmed: 10795602
J Infect Dis. 2003 Jun 15;187(12):1924-33
pubmed: 12792869
Medicine (Baltimore). 2016 Nov;95(44):e5257
pubmed: 27858889
Hepatology. 2014 Jan;59(1):89-97
pubmed: 23897861
PLoS One. 2012;7(6):e39175
pubmed: 22737229